Background: HDHD2 (haloacid dehalogenase-like hydrolase domain containing 2) is also known as DKFZp564D1378 and is a 259 amino acid protein that is expressed as two isoforms produced by alternative splicing. HDHD2 belongs to the HAD-like hydrolase superfamily, which contains a group of hydrolase enzymes that differ from the α/β hydrolase family based on structure. This family of hydrolase enzymes includes L-2-haloacid dehalogenase, epoxide hydrolases and phosphatases. HDHD2 has two active sites, an L-2-haloacid dehalogenase and a carboxylate group. The L-2-haloacid dehalogenase active site catalyzes the hydrolytic dehalogenation of D- and L-2-haloalkanoic acids, producing L- and D-2-hydroxyalkanoic acids. The gene encoding HDHD2 maps to human chromosome 18. Deletions within chromosome 18q can lead to deafness, blindness or mild facial dysmorphism. In addition, there are a variety of diseases associated with defects in chromosome 18-localized genes, some of which include Trisomy 18 (also known as Edwards syndrome), Niemann-Pick disease, hereditary hemorrhagic telangiectasia, erythropoietic protoporphyria and follicular lymphomas.
Description: Rabbit polyclonal to HDHD2
Immunogen: KLH conjugated synthetic peptide derived from HDHD2
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 29 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
